Investigations of the quality medicines distributed in Myanmar and Cambodia, through different surveys by ムハンマド ラフィクル イスラム & MD Rafiqul Islam
^>ªz¤} 
    Medicines are the most essential things especially for human beings to survive in the world. But, 
it is increasing the amount of counterfeiting or substandard medicines in the markets and ultimately 
supply to the patient’s day by day. Falsified or substandard medicines can present a health hazard to 
us. I have been attempting to clarify how often we might encounter such medicines and also to 
identify the specific features of defects to find clues for improvement. Despite of our results, much 
remains to be studied. Therefore, I reviewed the quality of medicines for lifestyle diseases in 
Cambodia for three years, and the quality of antimicrobial medicines in Cambodia for four years. In 
addition, I surveyed counterfeit or substandard medicines in Yangon, Myanmar survey in 2014 for 
collecting more data. I conducted a four-year and three-year study to evaluate the quality of selected 
antimicrobials and lifesaving medicines and to examine the prevalence of falsified or substandard 
antimicrobial and lifesaving medicines in Cambodia, aiming to promote efforts to improve the 
quality of medicines. I collected samples of clarithromycin, sulfamethoxazole/trimethoprim, 
ceftriaxone, cefuroxime, levofloxacin, gentamicin, ciprofloxacin, fluconazole, nalidixic acid, 
ofloxacin, phenoxymethyl penicillin and roxithromycin medicines as well as cimetidine, amlodipine, 
esomeprazole, rabeprazole, glibenclamide and metformin from pharmacies, Depot-A, Depot-B, 
wholesalers and non-licenced drug outlets in five provinces (rural areas) and Phnom Penh (an urban 
area), during 2011 to 2014 (antimicrobial) and 2011 to 2013 (lifesaving) Table 1& 2. 
 
    The authenticity of the collected medicines was investigated, and the medicines were analyzed 
to determine whether they met the appropriate pharmacopeial standards. I collected 647 samples, 
produced by 179 manufacturers, from 353 outlets. Only 51 (15%) of the outlets were air-conditioned. 
I found different-coloured packaging of the same brand (different lots) of products from some 
manufacturers. The insert information of one sample was different from the package information.  
 Twelve (1.9%) samples were not officially registered with DDF. In authenticity investigation, 43 of 
179 manufacturers replied and confirmed the authenticity of 154 samples (out of 647); also, 18 out of 
54 MRAs replied to enquiries about whether products were licensed or not (one was not). Among the 
samples, 424 (80.4%), 406 (86%) and 533(90.6%) passed in dissolution, content uniformity and 
quality tests, respectively (Table-3). Samples of cefuroxime and roxithromycin that failed were 
significantly cheaper than those that passed. Poor-quality antimicrobial medicines were found in 
Cambodian markets, though no falsified medicines were detected. Manufacturers should be 
encouraged to improve GMP implementation. Storage conditions in the distribution chain may also 
need to be improved. Continuous efforts by MRAs are needed to ensure that medicines are properly 
licensed. 
 
    In the case of three-year survey, we found 342 samples (223 from Phnom Penh) were collected 
from 263 outlets; among them, 32 (9.4%) had no inserts, and 14 (4.1%) were not registered with 
DDF. 38 (11.1%) were domestically produced. The containers of one amlodipine and three 
cimetidine samples were different from those of authentic samples. Nonstandard inserts were found 
in two samples (amlodipine and metformin). Only 21/81 manufacturers and 16/35 MRAs replied 
during authenticity investigation. In quality evaluation, 38 (11.1%), 52 (15.2%) and 48 (14%) 
samples failed dissolution, 
content uniformity and quantity 
tests, respectively (Table-4). The 
failure rate in quality tests was 
significantly associated with the 
results of visual analysis of 
samples. Poor-quality medicines 
were prevalent in Cambodia in 
2011-2013. Further surveys 
should be conducted to monitor the situation. Measures are desirable to improve the quality of 
domestically manufactured products.  
    The availability of substandard or counterfeit medicines in Myanmar was examined by the 
WHO in 1999, but no further systematic survey on counterfeit medicines has been conducted in the 
country since then. Samples of oral medicines, cefuroxime axetil (CXM), donepezil hydrochloride 







Myanmar in 2014 
(Table 5).  
    Authenticity and registration were verified. Quality tests of samples were performed according 
to the pharmacopeia indicated on the label. There were 221 (94%) foreign medicines among 235 
samples collected from 75 locations. Five samples of GM and 1DN sample were not registered with 
Myanmar Food and Drug Administration (MFDA). In quality analysis, 36 samples out of 177 
(20.3%) did not pass quantity tests, 27 samples out of 176 (15.3%) did not pass content uniformity 
tests, and 23 out of 128 samples (18.0%) did not pass dissolution tests (Table-6). Three of the 
unregistered GM samples failed in both identification and microbial assay tests (Fig. 1, 2 & 3). 
Counterfeit GM is being sold in Yangon. Also, the quality of OM is a matter of concern, and requires 
follow-up. Poor-quality medicines were frequently found among the products of a few manufacturers. 
Regular surveys to monitor counterfeit and substandard medicines in Myanmar are recommended. 
 
 
    I found that poor-quality 
medicines are the urgent problems in 
Cambodia and Myanmar, even 
though the medicines were not 
counterfeit. Serious dissolution 
failure is the dominant problem in 
these countries.  It is necessary to 
collect more information of such 
medicines, and to analyze the 
characteristics of the data for 
preventing health hazards caused by 
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